Palisade Capital Management LLC NJ purchased a new stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,043 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in Aerie Pharmaceuticals by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after buying an additional 49,473 shares in the last quarter. BlackRock Inc. raised its position in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after buying an additional 3,739 shares in the last quarter. Turner Investments LLC purchased a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $227,000. Finally, Vanguard Group Inc. raised its position in Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after buying an additional 92,463 shares in the last quarter. Institutional investors and hedge funds own 92.98% of the company’s stock.

Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 51.90 on Thursday. The firm’s market capitalization is $1.89 billion. Aerie Pharmaceuticals, Inc. has a 1-year low of $17.64 and a 1-year high of $59.50. The firm has a 50-day moving average price of $54.76 and a 200-day moving average price of $47.90.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. On average, analysts forecast that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/palisade-capital-management-llc-nj-purchases-shares-of-4043-aerie-pharmaceuticals-inc-aeri/1468617.html.

AERI has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $69.00 price target on shares of Aerie Pharmaceuticals in a research report on Wednesday, May 3rd. Needham & Company LLC raised their price target on Aerie Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, May 25th. Cowen and Company restated an “outperform” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Tuesday, April 18th. Canaccord Genuity set a $56.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 22nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $66.08.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.36% of the stock is currently owned by corporate insiders.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.